Telehealth company Hims & Hers Health (NYSE: HIMS) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 49.2% year on year to $599 million. On the other hand, next quarter’s revenue guidance of $615 million was less impressive, coming in 2.6% below analysts’ estimates. Its GAAP profit of $0.06 per share was 40.5% below analysts’ consensus estimates.

Is now the time to buy HIMS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth driven by surging demand for personalized care, new specialty launches, and expanding international reach. Management credited its vertically integrated compounding infrastructure and the transition to multi-condition daily treatments for fueling scale and efficiency. CEO Andrew Dudum highlighted that “subscribers using personalized solutions grew 50% year-over-year,” underscoring the company’s evolution from serving narrow health needs to supporting a broad array of conditions. The company’s ability to leverage its growing customer base for improved engagement and operational learnings featured prominently in its assessment of the quarter.

Looking ahead, management’s guidance reflects expectations for continued investment in new specialties, diagnostic capabilities, and international expansion, though near-term margin pressures are anticipated as a result. CEO Andrew Dudum pointed to the upcoming launch of whole body lab testing and the planned longevity specialty as key growth drivers, stating, “We envision these capabilities empowering consumers to proactively address health concerns.” The company also emphasized its strategy to deepen partnerships, broaden its product assortment, and scale internationally, particularly in Canada and Europe, while balancing these initiatives against targeted margin improvements over the longer term.

Key Insights from Management’s Remarks

Management attributed the quarter’s momentum to rapid growth in personalized care, investments in vertical integration, and the expansion of new specialties and international markets.

• Personalized care adoption: Hims & Hers Health’s shift toward personalized, multi-condition solutions led to a 50% year-over-year increase in subscribers using these offerings, strengthening customer retention and engagement.
• Weight loss platform expansion: The company’s weight loss specialty continued to see robust demand, supported by verticalized compounding operations and recent price reductions for GLP-1 treatment plans, which management expects will broaden access and drive future growth.
• New specialty launches: Recent introductions of low testosterone and menopause offerings, alongside planned launches of comprehensive lab testing and a longevity specialty, aim to address unmet needs across broader demographics and deepen relationships with existing customers.
• International growth acceleration: The integration of Zava Global expanded reach into the U.K., Germany, France, Ireland, and Spain, with management targeting Canada next. Early traction in these markets supports the company’s goal of becoming a leading global consumer health platform.
• Operational investments and efficiencies: While gross margin declined due to shifts in weight loss shipping cadence and integration expenses, marketing efficiencies and improved retention offset some cost pressures. Management continues to invest in technology and facility expansion to support future specialty launches and scale.

Drivers of Future Performance

Guidance for the coming quarters is shaped by ongoing investments in specialty offerings, technology, and new markets, with management emphasizing both growth opportunities and temporary margin headwinds.

• Broader specialty portfolio: Management expects the upcoming launches of whole body lab testing and a longevity specialty, together with expansion in menopause and testosterone care, to drive subscriber growth and deepen engagement, though these will require continued investment in operational scale and technology.
• Margin pressures and normalization: Shifting fulfillment to new facilities and lowering prices for certain weight loss treatments are expected to create temporary margin headwinds, with management projecting normalization and recovery as new customer cohorts accumulate and verticalization efforts mature.
• International market expansion: Entry into Canada and ongoing investments in European operations are central to the company’s growth strategy. Management sees these new geographies as significant contributors to long-term revenue, while also noting the need for tailored clinical networks and regulatory navigation in each market.

Catalysts in Upcoming Quarters

In the quarters ahead, StockStory analysts will closely track (1) the rollout and adoption rates of whole body lab testing and the planned longevity specialty, (2) the normalization of margins as verticalization and fulfillment investments mature, and (3) progress in expanding reach across Canada and Europe with tailored clinical networks. Execution on these fronts will be crucial for sustaining growth and delivering on management’s long-term targets.

Hims & Hers Health currently trades at $45.93, up from $44.38 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.